TRC041266
/ Torrent Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 27, 2022
Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P3 | N=0 | Withdrawn | Sponsor: Torrent Pharmaceuticals Limited | N=800 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus
August 11, 2020
Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P3; N=800; Not yet recruiting; Sponsor: Torrent Pharmaceuticals Limited
Clinical • New P3 trial • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 2
Of
2
Go to page
1